Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

Three decades ago, a scientist at the University of Texas named Bruce Beutler asked the U.S. government to grant him a patent for a new invention. Beutler, who would later win the Nobel Prize for his ...

Lilly is testing out a new kind of drug delivery model with its program, aiming to help patients connect with physicians and then support them in obtaining any treatments that get prescribed. The ...

Permission granted by Ed Shipman for Mass Eye and Ear When Misty Lovelace was a baby, her eyes were drawn to the light. She could not focus on faces, only sources of light. Her grandmother Cynthia ...

Bain Capital Life Sciences said Tuesday it has secured about $3 billion for its fourth fund, bringing the private investment firm’s total haul since its 2016 inception to $6.7 billion. Bain Capital ...